A US Food and Drug Administration (FDA) advisory committee has voted by 16 to one that data support the safety and effectiveness of Paxlovid (nirmatrelvir/ritonavir) for mild-to-moderate COVID-19 in adults at high risk for progression to severe illness.
The Antimicrobial Drugs Advisory Committee’s (AMDAC) vote will be considered by the FDA when making its decision regarding the potential permanent approval of Pfizer’s (NYSE: PFE) antiviral drug, which was granted emergency authorization in December 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze